Pharma is at a most critical point in its evolution. It is being held back by a lack of flexibility, speed and mastery of analytical power. The R&D process that has been its foundation now underpins an inefficient clinical trial process that is costly, often unprofitable and which makes it harder to successfully meet the changing and challenging demands of disease in the 21st century. The model of three fixed study phases is no longer viable to produce the therapeutic solutions that are required to meet increasingly complex healthcare demands dominated by an aging population with multiple health needs. ICON has undertaken research, assisted by ISR Research, and conducted an industry survey with Informa’s Pharma Intelligence, to examine the challenges facing pharma and find solutions.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.